At the AstraZeneca sponsored-symposium, held in conjunction with Diabetes Asia 2019, a panel of distinguished speakers spoke about the importance of preventing cardiovascular (CV) and renal complications in patients with type 2 diabetes mellitus (T2DM), in addition to addressing glucose control. Chaired by Professor Dato’ Dr Mafauzy Mohamed, the panel discussed updated outcomes of landmark studies supporting the benefit of dapagliflozin (Forxiga®, AstraZeneca) in patients with T2DM.
In pregnant women with prediabetes or pregestational type 2 diabetes (T2D), metformin also yields protective effects on the risk of pre-eclampsia, as shown in two studies presented at the Society for Maternal-Fetal Medicine (SMFM) 40th Annual Pregnancy Meeting.
In a lecture tour series organised by Boehringer Ingelheim Malaysia, Professor Michael Cummings spoke on the latest linagliptin analyses that shed new light on the long-term safety profile of the dipeptidyl peptidase-4 (DPP-4) inhibitor across a broad range of patients with type 2 diabetes (T2D).
Nondiabetic renal disease (NDRD) in patients with diabetes is frequently caused by nephroangiosclerosis, and the risk of NDRD is high in the absence of diabetic retinopathy and in elderly patients with microhaematuria, as reported in a recent study. However, compared with NDRD, diabetic nephropathy (DN) is associated with worse renal prognosis and higher mortality.
Higher concentrations of distinct ceramide species, known to be linked to adverse metabolic health, are associated with cumulative sugar-sweetened beverage (SSB) consumption that contributes to the development of cardiometabolic diseases, suggests a study.
Impaired fasting glucose appears to be a stronger risk factor for type 2 diabetes mellitus (T2DM) than metabolic syndrome (MetS), reports a new Japan study. The coexistence of the two factors confers the highest T2DM risk.
A robust association exists between improvements in carbohydrate quality index (CQI) and concurrent favourable cardiovascular disease (CVD) risk factor changes maintained over time in overweight/obese adults with metabolic syndrome (MetS), according to a study.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.